Blog
RSS FeedPosted by Michael Wonder on 07 Sep 2016
IQWiG Autumn Symposium 2016: programme is now online
6 September 2016 - More light than shadow? Beneficial and hindering factors for successful clinical studies. ...
Posted by Michael Wonder on 05 Sep 2016
Eisai bewildered as Germany's IQWIG fails to recognise additional benefit of Halaven (eribulin mesylate) in the treatment of advanced liposarcoma
4 September 2016 - Assessment ignores unprecedented overall survival benefit for eribulin in advanced liposarcoma. ...
Posted by Michael Wonder on 01 Sep 2016
Elotuzumab in multiple myeloma: additional clinical benefit is not proven
1 September 2016 - The only study available was unsuitable for the benefit assessment. ...
Posted by Michael Wonder on 17 Aug 2016
German body calls for pause in European plan for fast track drug approval
16 August 2016 - Plans by the European Medicines Agency to expand its fast track approach to approving new drugs have ...
Posted by Michael Wonder on 16 Aug 2016
German agency criticizes European program for speeding some drug approvals
15 August 2016 - in pointed remarks, Germany’s cost-effectiveness watchdog has criticized an effort by European regulators to accelerate approval ...
Posted by Michael Wonder on 09 Aug 2016
Adaptive pathways: EMA still leaves open questions unanswered
9 August 2016 - Current EMA report on the pilot project again documents perplexity regarding the use of “real world data”. ...
Posted by Michael Wonder on 06 Aug 2016
Brivaracetam in epilepsy: additional clinical benefits not seen as before
4 August 2016 - The new indirect comparison is methodologically better but there is still no evidence of an additional ...
Posted by Michael Wonder on 03 Aug 2016
Germany plans to extend price brake for drugs under statutory insurance
25 July 2016 - Germany wants to extend a price brake for drugs covered by statutory health insurance for five years ...
Posted by Michael Wonder on 03 Aug 2016
Ramucirumab in gastric cancer: no sign of an additional clinical benefit
1 August 2016 - Former orphan drug undergoes regular early benefit assessment; submitted studies unsuitable for assessment. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in advanced lung cancer: evidence for significant additional benefits
1 August 2016 - Advantages in overall survival and side effects. ...
Posted by Michael Wonder on 03 Aug 2016
Nivolumab in renal cell carcinoma: indication of additional clinical benefits
1 August 2016 - Benefits in overall survival, morbidity and side effects. ...
Posted by Michael Wonder on 02 Aug 2016
Afatinib dimaleate for patients with advanced squamous cell carcinoma of the lung: additional clinical benefits not there says IQWiG
1 August 2016 - Submitted comparisons for the benefit assessment are unsuitable. ...
Posted by Michael Wonder on 02 Aug 2016
Ospemifene in vulvovaginal atrophy: additional clinical benefits not seen says IQWiG
1 August 2016 - Incorrect study population, studies were too short. ...
Posted by Michael Wonder on 02 Jul 2016
Idelalisib in the second-line treatment in CLL: additional benefits still not seen
1 July 2016 - EMA safety review invokes reassessment but still no relevant data. ...
Posted by Michael Wonder on 02 Jul 2016
Necitumumab in NSCLC: small additional benefit for patients with metastases
1 July 2016 - Survival advantage, but also disadvantages. ...